case study/BPH

Mr. E is a pleasant, 70-year-old, black, male

Source: Self, reliable source

Subjective:

Chief complaint: “I urinate frequently.”  

HPI:  Patient states that he has had an increase in urination for the past several years, which seems to be worsening over the past year. He estimates that he urinates clear/light yellow urine approximately every 1.5-2 hours while awake and is up 2-4 times at night to urinate. He states some urgency and hesitancy with urination and feeling of incomplete voiding. He denies any pain or blood. Denies any head trauma. Denies any increase in thirst or hunger. He denies any unintentional weight loss.

Allergies: NKA

Current Mediations:

Multivitamin, daily

Aspirin, 81 mg, daily

Olmesartan, 20 mg daily

Atorvastatin, 10 mg daily

Diphenhydramine, 50 mg, at night                                                                                                                   

Pertinent History: Hypertension, hyperlipidemia, insomnia

Health Maintenance. Immunizations: Immunizations up to date

Family History: No cancer, cardiac, pulmonary or autoimmune disease in immediate family members

Social History: Patient lives alone. He drinks one cup of caffeinated coffee each morning at the local diner. He denies any nicotine, alcohol or drug use. 

ROS: Incorporated into HPI

Objective:

VS – BP: 118/68, HR: 86, RR: 16, Temp 97.6, oxygenation 100%, weight: 195 lbs, height: 70 inches.

Mr. E is alert, awake, oriented x 3.  Patient is clean and dressed appropriate for age.

Cardiac: No cardiomegaly or thrills; regular rate and rhythm, no murmur or gallop

Respiratory: Clear to auscultation 

Abdomen: Bowel sounds positive. Soft, nontender, nondistended, no hepatomegaly           

Neuro: CN 2-12 intact                                                                                                                        

Renal/prostate: Prostate enlarged, non-tender. No asymmetry or nodules palpated

Labs:

Test Name

Result

Units

Reference Range

Color

Yellow

Yellow

Clarity

Clear

Clear

Bilirubin

Negative

Negative

Specific Gravity

1.011

1.003-1.030

Blood

Negative

Negative

pH

7.5

4.5-8.0

Nitrite

Negative

Negative

Leukocyte esterase

Negative

Negative

Glucose

Negative

mg/dL

Negative

Ketones

Negative

mg/dL

Negative

Protein

Negative

mg/dL

Negative

WBC

Negative

/hpf

Negative

RBC

Negative

/hpf

Negative

Lab

Pt’s Result

Range

Units

Sodium

137

136-145

mmol/L

Potassium

4.7

3.5-5.1

mmol/L

Chloride

102

98-107

mmol/L

CO2

30

21-32

mmol/L

Glucose

92

70-99

mg/dL

BUN

7

6-25

mg/dL

Creat

1.6

.8-1.3

mg/dL

GFR

50

>60

Calcium

9.6

8.2-10.2

mg/dL

Total Protein

8.0

6.4-8.2

g/dL

Albumin

4.5

3.2-4.7

g/dL

Bilirubin

1.1

<1.1

mg/dL

Alkaline Phosphatase

94

26-137

U/L

AST

25

0-37

U/L

ALT

55

15-65

U/L

Pt’s results

Normal Range

Units

WBC

9.9

3.4 – 10.8

x10E3/uL

RBC

4.0

3.77 – 5.28

x10E6/uL

Hemoglobin

11.5

11.1 – 15.9

g/dL

Hematocrit

35.0

34.0 – 46.6

%

MCV

85

79 – 97

FL

MCH

28

26.6 – 33.0

Pg

MCHC

34

31.5 – 35.7

g/dL

RDW

14

12.3 – 15.4

%

Platelets

220

150 – 379

X10E3/uL

PSA

5.4

0-4.0

ng/mL

Assessment:

Diagnosis: Benign prostatic hyperplasia, ICD-10: N40.1

Please answer the following:

For the sake of this case study, the patient has confirmed BPH and prostate cancer has already been ruled out. Hence, please document your prescribed treatment plan for this patient (i.e. don’t state “refer to urology”).

  1. What is your treatment plan (include specific dosage and frequency)? Why did you choose this treatment plan? Do you change any of his current medications?  In your answer, please describe, briefly, the pharmacodynamics (1 point) and pharmacokinetics (1 point) of your treatment choice and how they influenced your decision. Does the patient have any comorbidities that influenced your choice as well (1 point)? 

       Three months later, the patient notes improvement, but no resolution of symptoms. What would be your next prescribed treatment option (1 point)?

  1. Document the education you would provide for this patient, specific to the prescribed medication. Please include information pertinent to the patient (2 points) and common potential adverse effects (2 points).